Skip to main content
Clinical Trials/EUCTR2004-002798-21-SK
EUCTR2004-002798-21-SK
Active, Not Recruiting
Phase 1

A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella

F.Hoffmann-La Roche Ltd0 sites300 target enrollmentMay 30, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
F.Hoffmann-La Roche Ltd
Enrollment
300
Status
Active, Not Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 30, 2005
End Date
August 24, 2006
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients will qualify to participate in this study if they meet all of the following:
  • 1\. Are male or female patients greater than or equal to 18 years of age that require hospitalization with community\-acquired pneumonia or develops pneumonia within 48 hours of hospitalization for another condition.
  • 2\. Have fever defined as body temperature \> 38\.0°C (100\.4°F) taken orally; or \> 38\.5°C (101\.2°F) tympanically; OR have hypothermia, defined as rectal or core body
  • temperature \< 36°C (96\.8°F).
  • 3\. Have a new or increased cough productive of purulent sputum for culture and
  • susceptibility testing.
  • 4\. Have either pleuritic chest pain, dyspnea, or tachypnea.
  • 5\. Have auscultatory findings consistent with pneumonic consolidation or pneumopathic process consistent with the diagnosis of pneumonia.
  • 6\. Have chest x\-ray confirmation of infiltrate or lobar consolidation.
  • 7\. Have obtained respiratory secretion specimen and two blood cultures prior to administration of IV study drug or non\-study short acting third generation cephalosporine. (Respiratory

Exclusion Criteria

  • Patients will be excluded if they meet any of the following:
  • 1\. Have a Pneumonia Severity Index \<71 or \>130\.
  • 2\. Have presented with sustained shock, defined as systolic blood pressure \< 90 mm Hg for \> 2 hours despite adequate fluid resuscitation, with evidence of hypoperfusion or need for sympathomimetic agents to maintain blood pressure.
  • 3\. In the opinion of the investigator, history, physical examination and chest X\-ray
  • findings are most consistent with an atypical pneumonia.
  • 4\. Require endotracheal intubation and ventilation, or in the opinion of the investigator, are expected to require it.
  • 5\. Are likely to be discharged in less than 3 days.
  • 6\. Developed pneumonia after more than 48 hours of admission to hospital.
  • 7\. Have been a resident in a nursing home or extended care facility within 60 days prior to randomization.
  • 8\. Require hemodialysis, peritoneal dialysis, plasmapheresis or hemoperfusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella - CAPTURECommunity-acquired pneumonia
EUCTR2004-002798-21-LVF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
N/A
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella
EUCTR2004-002798-21-LTF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
N/A
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of LegionellaCommunity-acquired pneumonia
EUCTR2004-002798-21-HUF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
Phase 1
The effect of SJX-653 on Menopausal Hot FlushesTreatment of moderate to severe vasomotor symptoms (VMS) associatedwith menopause.MedDRA version: 21.1Level: LLTClassification code 10027311Term: Menopause flushingSystem Organ Class: 100000004872Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
EUCTR2019-002281-12-GBSojournix, Inc.66
Unknown
Phase 2
A Clinical Study of NTx-265: human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in acute ischemic stroke patients
CTRI/2008/091/000262Stem Cell Therapeutics Corp